Leading a transformation in cancer care, where each patient’s treatment is informed by a deep understanding of the molecular changes that contribute to their disease


Foundation Medicine (NASDAQ:FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.


Year Invested: 2010
Location: Cambridge, Mass.
Visit: www.foundationmedicine.com

Recent News

April 20, 2017
Foundation Medicine Announces Timing for First Quarter 2017 Financial Results and Conference Call

March 30, 2017
Bristol-Myers Squibb Enters Collaboration to Leverage Foundation Medicine's Molecular Information Platform to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

March 2, 2017
Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company's Comprehensive Genomic Profiling Assay

Read More News

Associated Team Members

Mark Levin
Partner

Alexis Borisy
Partner

Neil Exter
Partner

Sarah Larson
Partner/Chief Human Resources Officer